sunvozertinib

Sunvozertinib is an oral, irreversible, mutant-selective **epidermal growth factor receptor** tyrosine kinase inhibitor developed by Dizal for **non-small cell lung cancer** driven primarily by **EGFR exon 20 insertion mutations**. It was rationally designed to inhibit a broad range of EGFR mutant forms while sparing wild-type EGFR, and preclinical and clinical reports also describe activity in other EGFR-mutant settings and exploratory activity in **HER2 exon 20 insertion** disease. Public sources and the provided trial/publication context identify sunvozertinib under the development code **DZD9008**; it received approval in China in 2023 and accelerated approval in the United States in 2025 for previously treated advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy. The drug is being studied across multiple WU-KONG trials in later-line, first-line, combination, and earlier-stage NSCLC settings, and global rights were licensed by AstraZeneca from Dizal in 2026.

Brand names

Zegfrovy舒沃哲

Other names

sunvozertinib舒沃替尼